Home » Stocks » Cleveland BioLabs

Cleveland BioLabs, Inc. (CBLI)

Stock Price: $2.24 USD 0.00 (0.00%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 28.94M
Revenue (ttm) 1.07M
Net Income (ttm) -2.36M
Shares Out 12.92M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $2.24
Previous Close $2.24
Change ($) 0.00
Change (%) 0.00%
Day's Open 2.22
Day's Range 2.21 - 2.42
Day's Volume 525,867
52-Week Range 0.50 - 5.00

More Stats

Market Cap 28.94M
Enterprise Value 27.52M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 12.92M
Float 4.92M
EPS (basic) -0.2
EPS (diluted) -0.21
FCF / Share -0.20
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10,981
Short Ratio 0.10
Short % of Float 0.39%
Beta 0.97
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 27.01
PB Ratio n/a
Revenue 1.07M
Operating Income -2.01M
Net Income -2.36M
Free Cash Flow -2.21M
Net Cash 1.42M
Net Cash / Share 0.11
Gross Margin -50.68%
Operating Margin -188.05%
Profit Margin -220.50%
FCF Margin -206.48%
ROA -44.62%
ROE -135.74%
ROIC 2,801.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$40.00*
Low
40.0
Current: 2.24
High
40.0
Target: 40.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1.111.141.953.522.713.708.493.578.7915.33
Revenue Growth-2.18%-41.58%-44.62%29.92%-26.84%-56.39%137.71%-59.38%-42.67%-
Gross Profit1.111.141.953.522.713.708.493.578.7915.33
Operating Income-2.36-4.80-5.60-6.36-10.79-14.42-23.08-30.05-25.11-10.74
Net Income-2.65-3.61-9.71-2.66-12.641.63-17.26-18.23-4.01-26.37
Shares Outstanding11.3011.2911.1910.997.062.702.251.871.631.31
Earnings Per Share-0.23-0.32-0.87-0.24-1.790.60-7.67-9.75-2.40-20.20
Operating Cash Flow-2.66-4.61-6.61-5.04-12.08-14.46-23.10-20.65-16.91-5.90
Capital Expenditures0.050.01-0.190.01-0.02-0.14-0.18-0.66-0.47
Free Cash Flow-2.61-4.61-6.61-4.85-12.07-14.48-23.24-20.83-17.56-6.36
Cash & Equivalents1.584.128.7915.2519.664.8013.2829.8628.3911.38
Total Debt-----4.157.560.17--
Net Cash / Debt1.584.128.7915.2519.660.665.7129.6928.3911.38
Assets2.044.539.6315.9620.889.8114.7032.0132.1319.89
Liabilities1.050.922.223.115.848.0313.1111.529.8832.39
Book Value-4.06-1.452.207.529.89-1.61-9.526.339.06-15.70
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cleveland BioLabs, Inc.
Country United States
Employees 7
CEO Christopher Zosh

Stock Information

Ticker Symbol CBLI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CBLI
IPO Date July 21, 2006

Description

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.